Freenome aims to take on the big beasts
Forthcoming data in colorectal cancer screening could put the company’s liquid biopsy on the market – but it looks like Guardant might get there first.
Liquid biopsy developers take aim at colorectal cancer
Natera and Guardant are about to shake things up with indication-specific blood tests, but Exact is keeping faith with Cologuard – for now.
A bad year to be an American medtech
Big-cap device makers on European exchanges did nicely in 2021, whereas their US-listed brethren had a harder time.
Guardant steps into a new arena
A test that tracks response to therapy is useful, but approval and reimbursement will be key.
Asco 2021 – Guardant shoots for the moon
And an expanded market awaits its colorectal cancer blood test, though Exact will benefit first.
